AN2 Therapeutics (ANTX) Other Non Operating Income (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Other Non Operating Income of $1.3 million for Q3 2024, down 13.99% year-over-year from $1.5 million in Q4 2023, and up 126600.0% quarter-over-quarter from $1000.0 in Q1 2024.
AN2 Therapeutics (ANTX) Other Non Operating Income (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Other Non Operating Income for 4 consecutive years, with $1.3 million the latest figure, recorded in Q3 2024.
- In Q3 2024, Other Non Operating Income fell 13.99% year-over-year to $1.3 million; the TTM figure through Dec 2024 stood at $1.3 million (up 2848.84% YoY), while the FY2025 annual figure was $1000.0, changed 0.0% from the prior year.
- Other Non Operating Income climbed to $1.3 million in Q3 2024 per ANTX's latest filing, from $1000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.5 million in Q3 2023 and bottomed at -$2.9 million in Q4 2023.
- Historically, Other Non Operating Income has averaged $198384.6 across 4 years, with a median of $213000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non Operating Income jumped 2781.82% — and 2023, when it sank 564.2%.
- AN2 Therapeutics' Other Non Operating Income stood at $22000.0 in 2021, then surged by 2781.82% to $634000.0 in 2022, then tumbled by 564.2% to -$2.9 million in 2023, then surged by 143.05% to $1.3 million in 2024.
- Business Quant data shows ANTX's Other Non Operating Income at $1.3 million in Q3 2024, $1000.0 in Q1 2024, and -$2.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | AN2 Therapeutics | 226.04 Mn | 226.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Sep 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | -2.94 Mn |
| Sep 30, 2023 | 1.47 Mn |
| Jun 30, 2023 | 797,000.00 |
| Mar 31, 2023 | 716,000.00 |
| Dec 31, 2022 | 634,000.00 |
| Sep 30, 2022 | 431,000.00 |
| Jun 30, 2022 | 213,000.00 |
| Mar 31, 2022 | 28,000.00 |
| Dec 31, 2021 | 22,000.00 |
| Sep 30, 2021 | -36,000.00 |
| Jun 30, 2021 | -24,000.00 |